Acute Myeloid Leukemia
Acute myeloid leukemia survival improved with high-dose cytosine arabinoside
Published in Clinical Oncology Week, August 28th, 2006
"The use of HDAraC during induction may improve outcomes in patients with AML compared with standard-dose AraC (SDAraC). The objective of this review was to assess the impact of HDAraC during induction therapy for patients with AML based on results from randomized trials," scientists in Germany reported.
"All randomized trials in the field were identified by using a pre-defined search strategy," explained W. Kern...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Clinical Oncology Week
More Articles from Clinical Oncology Week
- Colorectal Cancer
Colorectal cancer patients' poor survival predicted by presence of systemic inflammatory response - Head & Neck Cancer
Mucositis and dermatitis in head and neck cancer patients improved with zinc supplementation - Merkel Cell Cancer
Merkel cell carcinoma evaluated and managed by sentinel lymph node biopsy - Prostate Cancer
Early or adjuvant therapy might not benefit prostate cancer patients at low risk for recurrence - Acoustic Neuromas
House Clinic offers Gamma Knife technology as treatment for acoustic neuromas - Acute Myeloid Leukemia
ChemGenex publishes two new clinical studies supporting Ceflatonin beyond CML to other leukemias - More from this issue of Clinical Oncology Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
